Treatment value frameworks developed by the American Society of Clinical Oncology and the National Comprehensive Cancer Network do not adequately account for individual patient preferences, priorities and circumstances, limiting the tools' utility, write professor and insurance design expert Jalpa Doshi and colleagues. The Patient-Perspective Value Framework developed by FasterCures and Avalere captures more patient-specific factors, and a study led by CancerCare identified additional needs and challenges that developers of cancer treatment decision tools must consider.
This Thursday, March 22, FasterCures will be hosting a webinar titled: "Patient-Centered Measurement: How Close Are We?" When it comes to medical product discovery, development and delivery, patients need to be front and center -- but how close (or far away) are we from having a system that routinely measures what matters to patients? A panel of industry, regulatory and patient leaders will discuss what's next for patient-centered measurement. Panelists will define patient-centered measurement; identify novel strategies for capturing patient-centered outcomes; assess the progress in product development, regulatory approval, and delivery; and address how to advance the science of patient input in a way that fulfills the unmet needs of patients across diseases. Register today!
Catch Cynthia Grossman, director of science of patient input at FasterCures, a Center of the Milken Institute, on Levine Media Group's The Bio Report podcast! She discusses why patient-reported outcome measures and patient-centric outcomes are not one and the same, and what can be done to better reflect what matters to patients. Learn about the challenges and opportunities surrounding the creation and implementation of patient-centered, patient-reported outcomes. Listen to the podcast.
Drugmakers derive the bulk of their revenue from older drugs, creating an incentive to protect market share instead of developing novel products, says FasterCures Senior Fellow Bernard Munos. Drug company executives noted the lack of a "fail fast" culture, but few cited regulations as a barrier to success.
Vanderbilt University Medical Center researchers created an EHR data mining technique to detect undiagnosed genetic diseases, according to a study published in the journal Science. Researchers applied phenotype risk scores to almost 22,000 genotyped patients and found a correlation between rare genetic variants and severe outcomes including organ transplants in 16 patients, and 18 ties between rare genetic variants and phenotypes consistent with Mendelian diseases.
Prior chemotherapy appears to limit the expansion and efficacy of chimeric antigen receptor T cells in children with certain types of cancer, according to research reported in advance of the annual meeting of the American Association for Cancer Research. Specific types of chemotherapeutic drugs, such as doxorubicin and cyclophosphamide, were associated with depleted T cell energy reserve, a sign of poor clinical performance, and efficacy appears to be influenced by the fuel pathways used by T cells. The findings could lead to alternate approaches "to make sure that we make a highly functional CAR T-cell product, not only for kids with leukemia but also for potentially solid-tumor CARs, as we try to develop those in the future," said Dr. David Barrett of Children's Hospital of Philadelphia.
Drugmakers are focusing more attention and money on digital health technology as software developers create methods for using video games, smartphone apps and sensors to help patients manage chronic conditions and illnesses. Instead of being sold directly to consumers from an online store, digital therapeutics are being submitted for FDA approval and, increasingly, covered by insurance.
The National Institute of Allergy and Infectious Diseases will allocate $12 million from its budget for fiscal year 2019 to establish two to three new genomic research centers for infectious disease. These new Genomic Centers for Infectious Diseases will become large-scale genomic resources that will make sequencing and experimental data accessible to the infectious disease research community.
Nike co-founder Phil Knight and his wife, Penny, have committed $500 million toward the construction of a cutting-edge science center at the University of Oregon. The university will also receive $70 million from the state to go toward the $1 billion facility, but it will have to come up with the additional $430 million needed to complete the project.
A round of Series C funding pulled in $55 million for Unity Biotechnology, which develops candidates for age-related diseases. Unity's UBX0101 is anticipated to enter clinical study this half for osteoarthritis and its UBX1967 is in preclinical testing for diabetic retinopathy, diabetic macular edema, glaucoma and age-related macular degeneration.
Medicare will now cover next-generation DNA sequencing to guide treatment of stage III and IV cancers as well as recurrent, metastatic, relapsed or refractory disease. The decision follows the agency's review of the FoundationOne CDx test, which identifies mutations in 324 genes and two genomic signatures in solid tumors, and the CMS said it will cover similar tests once approved.
Standardizing, sharing and putting the power of data into patients' hands would improve the patient experience as well as research, and data silos must be razed quickly, writes former Vice President and Biden Cancer Initiative Co-chair Joe Biden. He presents four specific steps the HHS and the National Cancer Institute should take that would reduce costs and improve outcomes, interoperability and access to data.
Discover FasterCures'Health Data Basics project to find resources on health data access, insights from industry leaders, and patient and caregiver perspectives.
FasterCures is an action tank that works across sectors and diseases to improve the effectiveness and efficiency of the medical research enterprise. FasterCures, a center of the Milken Institute, is nonpartisan and independent of interest groups.
1101 New York Avenue, NW
Washington, DC 20005
(202) 336-8900 |